Literature DB >> 19167499

Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS.

Chuanhai Cao1, Gary W Arendash, Alexander Dickson, Malgorzata B Mamcarz, Xiaoyang Lin, Douglas W Ethell.   

Abstract

We have found that a small number of purified Th2-biased Abeta-specific T cells are sufficient to provide profound cognitive and pathological benefits in an APP+PS1 mouse model for Alzheimer's disease. Six weeks after receiving T cell infusions, cognitively-impaired mice performed significantly better in working memory tasks, which correlated with higher plasma levels of soluble Abeta. Pathological analysis of the hippocampus revealed a 30% decrease of plaque-associated microglia and less vascular amyloidosis in T cell treated mice. The infusion of Abeta-specific Th2 cells also reduced plasma levels of IFN-gamma, TNF-alpha, GM-CSF, IL-2 and IL-4, which are elevated in untreated APP+PS1 mice. No significant immune cell infiltration and no anti-Abeta antibody titers occurred in the T cell treated mice. These results demonstrate that Abeta-specific Th2 cells are sufficient to reverse cognitive impairment and provide multiple pathological benefits in an Alzheimer's mouse model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167499      PMCID: PMC5546306          DOI: 10.1016/j.nbd.2008.12.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

1.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

2.  Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients.

Authors:  A W Henkel; P S Dittrich; T W Groemer; E A Lemke; J Klingauf; H W Klafki; P Lewczuk; H Esselmann; P Schwille; J Kornhuber; J Wiltfang
Journal:  Mol Psychiatry       Date:  2007-02-06       Impact factor: 15.992

3.  Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice.

Authors:  Douglas W Ethell; Daniel Shippy; Chuanhai Cao; Jennifer R Cracchiolo; Melissa Runfeldt; Brett Blake; Gary W Arendash
Journal:  Neurobiol Dis       Date:  2006-05-30       Impact factor: 5.996

4.  Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.

Authors:  G W Arendash; W Schleif; K Rezai-Zadeh; E K Jackson; L C Zacharia; J R Cracchiolo; D Shippy; J Tan
Journal:  Neuroscience       Date:  2006-08-28       Impact factor: 3.590

5.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

6.  Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

Authors:  Sylvia Brettschneider; Nils G Morgenthaler; Stefan J Teipel; Christina Fischer-Schulz; Katharina Bürger; Richard Dodel; Yansheng Du; Hans-Jürgen Möller; Andreas Bergmann; Harald Hampel
Journal:  Biol Psychiatry       Date:  2005-04-01       Impact factor: 13.382

7.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.

Authors:  Masahisa Jinushi; Yukoh Nakazaki; Michael Dougan; Daniel R Carrasco; Martin Mihm; Glenn Dranoff
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs).

Authors:  Nilufer Esen; Tammy Kielian
Journal:  J Neuroinflammation       Date:  2007-03-20       Impact factor: 8.322

View more
  49 in total

1.  Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer's mice.

Authors:  Zhongqiu Luo; Jialin Li; Neel R Nabar; Xiaoyang Lin; Ge Bai; Jianfeng Cai; Shu-Feng Zhou; Chuanhai Cao; Jinhuan Wang
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-09       Impact factor: 4.147

2.  Cofilin under control of β-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning.

Authors:  Crystal G Pontrello; Min-Yu Sun; Alice Lin; Todd A Fiacco; Kathryn A DeFea; Iryna M Ethell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 3.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

4.  Alternatively activated myeloid (M2) cells enhance cognitive function in immune compromised mice.

Authors:  Noel C Derecki; Kayla M Quinnies; Jonathan Kipnis
Journal:  Brain Behav Immun       Date:  2010-11-18       Impact factor: 7.217

Review 5.  The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease.

Authors:  Marina A Lynch
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

6.  Commentary: IL-4 and IL-13 receptors and signaling.

Authors:  Sarah M McCormick; Nicola M Heller
Journal:  Cytokine       Date:  2015-07-14       Impact factor: 3.861

7.  High Blood caffeine levels in MCI linked to lack of progression to dementia.

Authors:  Chuanhai Cao; David A Loewenstein; Xiaoyang Lin; Chi Zhang; Li Wang; Ranjan Duara; Yougui Wu; Alessandra Giannini; Ge Bai; Jianfeng Cai; Maria Greig; Elizabeth Schofield; Raj Ashok; Brent Small; Huntington Potter; Gary W Arendash
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 8.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

9.  Regulation of learning and memory by meningeal immunity: a key role for IL-4.

Authors:  Noël C Derecki; Amber N Cardani; Chun Hui Yang; Kayla M Quinnies; Anastasia Crihfield; Kevin R Lynch; Jonathan Kipnis
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

10.  CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging.

Authors:  Kuti Baruch; Noga Ron-Harel; Hilah Gal; Aleksandra Deczkowska; Eric Shifrut; Wilfred Ndifon; Nataly Mirlas-Neisberg; Michal Cardon; Ilan Vaknin; Liora Cahalon; Tamara Berkutzki; Mark P Mattson; Fernando Gomez-Pinilla; Nir Friedman; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.